S García Hernández

Suggest Changes
Learn More
e18051 Background: EGFR mutations have been reported to be a predictor of efficacy of new drugs in NSCLC first line treatment. Recently, two phase III trials have shown the efficacy of gefinitib and(More)
  • 1